Zealand Pharma A/S
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zealand Pharma A/S
BI’s global head of innovation Michel Pairet tells In Vivo that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.
Public Company Edition: Neumora grossed $250m and RayzeBio raised $311m in the first initial public offerings since early August. Also, ImmunityBio completes $470m in equity and debt financings, Bausch + Lomb sells $1.4bn worth of notes and Arbutus is among firms making cuts to conserve cash.
The once-daily oral somatostatin receptor type 2 (SST2) agonist outshined placebo in patients switching from standard of care, offering an attractive alternative to once-monthly injectables.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Other Names / Subsidiaries
- Encycle Therapeutics, Inc.
- Valeritas Holdings, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.